TrialClinical and experimental immunology2014

VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis.

I Mendel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.